This company has been marked as potentially delisted and may not be actively trading. Travere Therapeutics (RTRX) News Today Add Compare Share Share Headlines Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock RTRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Travere Therapeutics Kicks Off “Play It Forward” Campaign for FSGS AwarenessJune 24, 2025 | msn.comTravere Therapeutics’ sNDA for FILSPARI accepted by FDAMay 17, 2025 | uk.investing.comIBD 50 Stock Travere Therapeutics Nosedived On An FDA Decision — Here's WhyMay 16, 2025 | msn.comTravere Stock Nosedives As FDA Schedules Advisory Meeting For Kidney Drug's Supplemental Use: Retail Shrugs Off WorriesMay 16, 2025 | msn.comTravere Therapeutics Rallies To Buy Point As Kidney Drug Sales Rocket 182%; Anticipates FDA Priority Review For FSGS TreatmentMay 6, 2025 | msn.comTravere Therapeutics anticipates FILSPARI approval for FSGS by September 2025May 2, 2025 | msn.comTravere Therapeutics price target lowered to $30 from $32 at ScotiabankApril 11, 2025 | markets.businessinsider.comTravere Therapeutics price target raised to $47 from $45 at CanaccordApril 11, 2025 | markets.businessinsider.comTravere Therapeutics price target lowered to $27 from $31 at BofAApril 4, 2025 | markets.businessinsider.comNovartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug ApprovalApril 3, 2025 | msn.comTravere Therapeutics price target raised to $31 from $29 at BofAApril 2, 2025 | markets.businessinsider.comTravere Therapeutics price target raised to $44 from $42 at JPMorganFebruary 26, 2025 | markets.businessinsider.comTravere Therapeutics (TVTX): Among The Small–Cap Stocks Insiders Are Selling RecentlyFebruary 14, 2025 | msn.comTravere to Seek FDA OK of Filspari in Rare Kidney Disorder FSGS; Shares RallyFebruary 11, 2025 | marketwatch.comTravere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease DrugFebruary 11, 2025 | msn.comTravere therapeutics CFO sells $104,463 in stockFebruary 5, 2025 | msn.comTravere therapeutics executive sells shares worth $106,081February 5, 2025 | msn.comTravere therapeutics chief commercial officer sells $30,002 in stockJanuary 25, 2025 | msn.comTravere Therapeutics price target raised to $22 from $18 at H.C. WainwrightJanuary 15, 2025 | markets.businessinsider.comStifel Nicolaus Sticks to Its Hold Rating for Travere Therapeutics (TVTX)January 14, 2025 | markets.businessinsider.comTravere Therapeutics sees Q4 net product sales $74MJanuary 13, 2025 | markets.businessinsider.comTravere Therapeutics Provides Corporate Update and 2025 OutlookJanuary 13, 2025 | markets.businessinsider.comKidney Disease Leader Travere Therapeutics Pulls Back To Key LevelNovember 20, 2024 | msn.comTravere Therapeutics 7.81M share Spot Secondary priced at $16.00November 8, 2024 | markets.businessinsider.comTravere Therapeutics announces common stock offering, no amount givenNovember 7, 2024 | markets.businessinsider.comTravere Therapeutics (TVTX) Gets a Buy from TD CowenNovember 6, 2024 | markets.businessinsider.comTravere Therapeutics: Strong Growth and Strategic Advancements Drive Buy RatingNovember 2, 2024 | markets.businessinsider.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call TranscriptNovember 1, 2024 | msn.comTravere Therapeutics price target raised to $27 from $23 at ScotiabankNovember 1, 2024 | markets.businessinsider.comTravere Therapeutics (TVTX) Gets a Buy from Bank of America SecuritiesNovember 1, 2024 | markets.businessinsider.comPositive FDA Prospects for Travere Therapeutics Boosts Buy RatingOctober 28, 2024 | markets.businessinsider.comEvercore ISI Sticks to Its Buy Rating for Travere Therapeutics (TVTX)October 28, 2024 | markets.businessinsider.comTravere Therapeutics (TVTX) Receives a Hold from Stifel NicolausOctober 28, 2024 | markets.businessinsider.comTravere presents data reinforcing clinical benefit of FILSPARI in IgANOctober 27, 2024 | markets.businessinsider.comTravere Therapeutics Highlights Clinical Benefits Of FILSPARI For IgA Nephropathy And FSGSOctober 26, 2024 | markets.businessinsider.comJim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money'October 24, 2024 | benzinga.comTravere Therapeutics Secures Swiss Authorization For FILSPARI To Treat IgA NephropathyOctober 17, 2024 | markets.businessinsider.comScotiabank Initiates Coverage of Travere Therapeutics (TVTX) with Sector Outperform RecommendationOctober 16, 2024 | msn.comTravere Therapeutics Hits 15-Month High On A Promising FDA 'Pivot' In Kidney DiseaseOctober 10, 2024 | msn.comStrong Buy Rating for Travere Therapeutics Backed by Filspari’s Market Potential and Full FDA ApprovalOctober 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics Amid Proactive HARMONY Study Management and Strong Financial StanceSeptember 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics Following Filspari’s Expanded FDA Approval and Positive Market OutlookSeptember 10, 2024 | markets.businessinsider.comTravere Therapeutics (TVTX) Gets a Hold from Wells FargoSeptember 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics Amid Positive KDIGO Guideline Developments and Filspari’s Market PotentialSeptember 4, 2024 | markets.businessinsider.comPiper Sandler Remains a Hold on Travere Therapeutics (TVTX)August 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Siegfried Holding AG (OtherSGFEF) and Travere Therapeutics (TVTX)August 5, 2024 | markets.businessinsider.comBuy Rating on Travere Therapeutics: Robust Filspari Sales and Strong Market Outlook Justify Outperform StatusAugust 5, 2024 | markets.businessinsider.comOptimistic Outlook for Travere Therapeutics Amidst Solid Performance and Favorable Regulatory ProspectsAugust 4, 2024 | markets.businessinsider.comTravere Therapeutics Poised for Continued Growth: A Buy Rating Based on Strong Financials and Market PotentialAugust 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Longboard Pharmaceuticals (LBPH) and Travere Therapeutics (TVTX)May 7, 2024 | markets.businessinsider.com Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter. Email Address RTRX Media Mentions By Week RTRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RTRX News Sentiment▼0.000.54▲Average Medical News Sentiment RTRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RTRX Articles This Week▼01▲RTRX Articles Average Week Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MorphoSys News Calliditas Therapeutics AB (publ) News Zymeworks News Chimerix News Avid Bioservices News MBX Biosciences News Revance Therapeutics News Checkpoint Therapeutics News Aerovate Therapeutics News 2seventy bio News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RTRX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RTRX Stock Alerts